Clinical trials: Advanced Malignant Tumor
Advanced Malignant Tumors
Phase I Study of LNF1901 in Advanced Malignant Tumors
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
- Trial name
- NCT06226363
- Testing
- LNF1901 Monoclonal Antibody Injection
- Volunteers
- 82 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Hilar Cholangiocarcinoma
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
This is a multi-center, randomized, controlled, open-label, phase IIa clinical study.The study will observe the efficacy and safety of Deuteporfin photodynamic therapy in addition to stenting compared to stenting alone in…
- Trial name
- NCT02955771
- Testing
- PDT-Deuteporfin（6 hour), PDT-Deuteporfin（9 hour), stenting
- Where
- 4 sites in China
- Volunteers
- 7 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Malignant Tumor
Phase I/II Clinical Trial of LBL-015 for Injection
A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-015 in Patients With Advanced Malignant Tumors.
- Trial name
- NCT05107011
- Testing
- LBL-015 for Injections
- Where
- 6 sites in China
- Volunteers
- 25 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Solid Tumors
Phase I Study in Advanced Solid Tumors
Dose escalating study of orally administered indibulin at twice daily schedule in subjects with solid tumors.
- Trial name
- NCT00591292
- Testing
- indibulin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Alaunos Therapeutics
Solid Tumor
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension).
- Trial name
- NCT04175847
- Testing
- RC88
- Where
- 4 sites in China
- Volunteers
- 198 people
- Sponsor
- RemeGen Co., Ltd.
Cancer, Lymphomas
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Multicenter, open-label study of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma whose disease had progressed after treatment with standard, approved therapies that included 2 stages.
- Trial name
- NCT00396864
- Testing
- NPI-0052
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Celgene
Advanced Solid Tumor, NSCLC
A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors
- Trial name
- NCT05417321
- Testing
- HB0036
- Where
- 4 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies
Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability, safety and pharmacokinetic profile of ASP1948 in Japanese patients with locally advanced (unresectable) or metastatic solid tumors.
- Trial name
- NCT04094506
- Testing
- ASP1948
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Inc
Hepatic Impairment, Solid Tumor
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
This is a multi-center, open-label, Phase 1 study to evaluate the impact of hepatic impairment on the pharmacokinetics of Tivantinib in cancer subjects with varying degrees of hepatic function, from normal to severely impaired.
- Conditions
- Hepatic Impairment, Solid Tumor, Cancer
- Trial name
- NCT02150733
- Testing
- Tivantinib
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Daiichi Sankyo
Solid Tumor, Advanced Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate safety and anti- tumor activity of Q702 administered…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT04648254
- Testing
- Q702
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Qurient Co., Ltd.
Malignant Melanoma
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.
- Trial name
- NCT00651703
- Testing
- CYT004-MelQbG10 + Montanide, CYT004-MelQbG10 + Montanide + Imiquimod, CYT004-MelQbG10 + Imiquimod
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Cytos Biotechnology AG
Advanced Solid Tumor (Phase 1)
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors.
- Trial name
- NCT07695142
- Testing
- HSK46256
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3…
- Conditions
- Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
- Trial name
- NCT05242822
- Testing
- KIN-3248
- Where
- 21 sites in United States, China and 4 more
- Volunteers
- 54 people
- Sponsor
- Kinnate Biopharma
Advanced Solid Tumor
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with…
- Trial name
- NCT06682780
- Testing
- LM-2417, Docetaxel, Toripalimab/Tirelizumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LaNova Medicines Limited
Advanced Solid Tumor
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets.
- Trial name
- NCT06198556
- Testing
- HRS-1167 tablets; rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumor
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated dose) and/or RP2D (recommended phase 2 dose)…
- Trial name
- NCT06126666
- Testing
- ABL103
- Where
- 3 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- ABL Bio, Inc.
Advanced Solid Tumor
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
- Trial name
- NCT06446388
- Testing
- QLS31905, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Solid Tumor
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced…
- Trial name
- NCT06241456
- Testing
- FT825, Fludarabine, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 351 people
- Sponsor
- Fate Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.